Fluocinolone acetonide/hydroquinone/tretinoin

Drug Profile

Fluocinolone acetonide/hydroquinone/tretinoin

Alternative Names: Hydroquinone/tretinoin/fluocinolone-acetonide; Tri-Luma

Latest Information Update: 10 Apr 2003

Price : $50

At a glance

  • Originator Hill Dermaceuticals
  • Developer Galderma
  • Class Fluorinated steroids; Hydroquinones; Pregnadienes; Retinoids; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Melanosis

Most Recent Events

  • 10 Apr 2003 Data presented at the 61st Annual Meeting of the American Academy of Dermatology (AAD-2003) have been added to the adverse events and Skin Disorders therapeutic trials section
  • 29 Apr 2002 Data from a media release have been added to the adverse events and Skin disorders therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top